Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial

Breast Cancer

Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial results

Clin Cancer Res

Roseshter T, Klemantovich A, Lafleur J, Lan C, Cavallone L, Bozek K, Guay J, Elebute O, Jenna S, Ouellette R, McNamara S, Boileau JF, Pelmus M, Brackstone M, Pezo R, Ng T, Aguilar-Mahecha A, Basik M

doi: 10.1158/1078-0432.CCR-25-2234

Breast Cancer

Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial

J Clin Oncol

Gupta S, Nair N, Hawaldar RW, Joshi S, Gulia S, Shet T, Sarin R, Parmar V, Desai S, Ghosh J, Wadasadawala T, Vanmali V, Panhale T, Parab P, Patil A, Chitkara G, Rath S, Bajpai J, Pathak R, Popat P, Thakur M, Badwe RA

doi: 10.1200/JCO-25-01023

Breast Cancer

A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial

Ann Oncol

Kim GM, Jung KH, Jeung HC, Lee J, Lee KS, Im SA, Kang SY, Kim SH, Kim HJ, Park KH, Chae YS, Koh SJ, Cho EK, Park KU, Lee SS, Kim JY, Choi IS, Baek SK, Moon YW, Kim SG, Lim ST, Lee KH, Kim HJ, Kim MH, Kim KH, Kim SI, Park S, Park HS, Kim JY, Kim YB, Kim SB, Ahn JH, Jeong JH, Kim JH, Jeong J, Park WC, Sim SH, Lee K, Nam CM, Park S, Paik S, Sohn J, Korean Cancer Study Group (KCSG)

doi: 10.1016/j.annonc.2026.05.703

Breast Cancer

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial

Ann Oncol

Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, Ribi K, Ruddy KJ, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Partridge AH, International Breast Cancer Study Group, POSITIVE Trial Consortium

doi: 10.1016/j.annonc.2026.05.699

Breast Cancer

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial

JAMA Oncol

Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ

doi: 10.1001/jamaoncol.2026.2576

Breast Cancer

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer

Lancet Oncol

Kaidar-Person O, Weltens CG, Fortpied C, Scheijmans LJEE, Kirkove CY, Budach V, Peignaux-Casasnovas K, Valli M, Peters M, van der Leij F, Rivera S, Weidner N, van den Bongard DHJG, Linsenmeier C, Abdah-Bortnyak R, Hosni S, Koiter E, Engelen AM, Baten A, Champezou L, Fourquet A, Bartelink HGMM, Struikmans H, Poortmans PMP, EORTC Radiation Oncology and Breast Cancer Groups

doi: 10.1016/S1470-2045(26)00233-0

Breast Cancer

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial

Clin Cancer Res

Jhaveri K, Eli LD, Hurvitz SA, Brufsky A, Bose R, de Miguel M, Unni N, Reid S, Quinn DI, Mahalingam D, Saura Manich C, García-Sáenz JÁ, Martínez-Bueno A, Guerrero-Zotano A, Trédan O, Wildiers H, Bischof GF, Bebchuk J, Solit DB

doi: 10.1158/1078-0432.CCR-25-4135

Breast Cancer

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer

Clin Cancer Res

Dieci MV, Gasparini E, Nicolè L, Schmid P, Zambelli A, Favaretto A, Piacentini F, Bianchi GV, Mion M, Ferro A, Arpino G, Emiliani A, Cinieri S, Zamagni C, Gennari A, Spazzapan S, Sartori D, Zustovich F, Tamberi S, Del Mastro L, De Laurentiis M, Musolino A, Cagossi K, Generali D, Giarratano T, Giovanardi F, De Salvo GL, Conte P, Guarneri V

doi: 10.1158/1078-0432.CCR-26-0975

RECOMMENDED

Breast Cancer

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY

doi: 10.1016/S1470-2045(25)00545-5

Related content

Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial results

Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial

A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial